Abstract:Introduction Cardiovascular disease remains the leading cause of mortality in pregnant women, with cardiomyopathy remaining the most common complication during pregnancy among all women with heart disease. Hypertrophic cardiomyopathy is increasingly diagnosed in more patients as a result of the improvement in screening methods and clinical awareness. Compared to an incidence of 0.2% (1 in 500) in the general population. Prevalence among pregnant women is low, making it a challenging disease for physicians and their patients. Method This was a retrospective analysis using the The National (Nationwide) Inpatient Sample (NIS) database. The inclusion criteria comprised all pregnant female patients dating from 2015 to 2000. Patient were divided into two groups based on having the diagnosis of HCM. Baseline patient characteristics and outcomes to be compared between the two groups. Results Our study also shows significant differences in baseline characteristics in pregnant patients with HCM. The incidence of HCM in pregnant women in our study is 0.005%. Other studies report an incidence of 0.015% to 0.2%. Although the majority of patients were white, black women had the highest prevalance (8:10,000) of hypertrophic cardiomyopathy compared to their control group. The odds of systemic organ disease are significantly higher in patients with HCM, including lung disease, renal failure, and obesity. Cardiovascular comorbidities are also significantly higher in patients with HCM, where they are more likely to suffer from cardiac arrhythmia, heart failure, valvular disease, and chronic hypertension. Although many of such comorbidities are likely independent of HCM, this highlights the importance of thorough prenatal assessment and evaluation to risk stratify this patient population. Outcomes were largely comparable between the two groups, however, patients with HCM were more likely to have preterm labor (OR: 3.64, p=0.01), intrauterine death (OR: 3.6, p=0.02), C-section (OR: 1.83, p<0.01), and instrumental delivery (OR: 12.75, p=0.02). Other obstetric complications including preeclamposa, placental disorders, and periparturm hemorrhage were not different between the two groups. In conclusion Pregnant women with hypertrophic cardiomyopathy are more likely to carry a higher burden of comorbidity in comparison to the general population. This may represent significant challenges to the patient and their caring physician. Outcomes however appear to be comparable between the two groups with hypertrophic cardiomyopathy being well tolerated during pregnancy. Significant risk of worse fetal outcomes and intrauterine death may be associated with HCM during pregnancy.

Disease features and management of cardiomyopathies in women

What Do We Know about Peripartum Cardiomyopathy? Yesterday, Today, Tomorrow

Peripartum cardiomyopathy: a comprehensive and contemporary review

Peripartum cardiomyopathy: A review

The "arrhythmic" presentation of peripartum cardiomyopathy: case series and critical review of the literature

Cardiomyopathies in Pregnancy: Trends and Clinical Outcomes in Delivery Hospitalizations in the United States (2005-2020)

The new 2023 ESC guidelines for the management of cardiomyopathies: a guiding path for cardiologist decisions

State-of-the-art document on optimal contemporary management of cardiomyopathies

Cardiomyopathy: pathogenesis and therapeutic interventions

Myocardial Posttranscriptional Landscape in Peripartum Cardiomyopathy

Hypertrophic Cardiomyopathy In Pregnancy: A Retrospective Study Of Patients Characteristics And Outcomes

Long‐term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Sex and gender differences in myocarditis and dilated cardiomyopathy: An update

Effect of Gender and Genetic Mutations on Outcomes in Patients With Hypertrophic Cardiomyopathy

Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy

Living with peripartum cardiomyopathy: A statement from the Heart Failure Association and the Association of Cardiovascular Nursing and Allied Professions of the European Society of Cardiology

Cardiovascular prevention in women: a narrative review from the Italian Society of Cardiology working groups on 'Cardiovascular Prevention, Hypertension and peripheral circulation' and on 'Women Disease'

Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies

Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy

Evolving concepts in dilated cardiomyopathy

Cardiovascular diseases in women: a differentiated view and risk stratification